WHO ICTRP trial
A single-arm, phase II trial of neoadjuvant SHR-1316 plus nab-paclitaxel and…
ChiCTR2300074152 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300074152 |
|---|---|
| Public title | A single-arm, phase II trial of neoadjuvant SHR-1316 plus nab-paclitaxel and carboplatin for potentially unresectable locally advanced thymic carcinomas |
| Scientific title | A single-arm, phase II trial of neoadjuvant SHR-1316 plus nab-paclitaxel and carboplatin for potentially unresectable locally advanced thymic carcinomas |
| Primary sponsor | Shanghai Chest Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | thymic carcinoma |
| Interventions | Test group: SH1316+ nab-paclitaxel+ carboplatin |
| Registration date | Jul 31, 2023 |
| Target size | Test group:27 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: